Key result
Patients with Postural Orthostatic Tachycardia Syndrome had lower plasma levels of proconvertase furin compared to individuals with a normal hemodynamic response.
Why the study?
The aetiology of POTS is uncertain, though autoimmunity and inflammation may play a role, prompting this search for novel inflammatory biomarkers associated with POTS.
Are specific inflammatory biomarkers altered in patients with Postural Orthostatic Tachycardia Syndrome compared to individuals with normal postural hemodynamic response?
Cross-Sectional (n=396)
No
Are specific inflammatory biomarkers altered in patients with Postural Orthostatic Tachycardia Syndrome compared to individuals with normal postural hemodynamic response?
Patients with POTS have significantly lower plasma levels of proconvertase furin, suggesting a potential autoimmune trait and disruption of immune peripheral tolerance in the syndrome's pathophysiology.
Answers are grounded in this paper and cite their sources.
Lower furin levels should not yet inform POTS care; this novel observation leaves open biomarker and mechanistic studies.
Background: Postural Orthostatic Tachycardia Syndrome (POTS) is a cardiovascular autonomic disorder characterized by orthostatic intolerance and high prevalence among young women. The aetiology of POTS is uncertain, though autoimmunity and inflammation may play an important role. We aimed to identify novel inflammatory biomarkers associated with POTS. Methods and Results: In the Syncope Study of Unselected Population in Malmö (SYSTEMA) cohort, we identified 396 patients (age range, 15-50 years) with either POTS (n=113) or normal haemodynamic response during passive head-up-tilt test (n=283). Blood samples were analyzed using antibody-based Proximity Extension Assay technique simultaneously measuring 57 inflammatory protein biomarkers. The discovery algorithm was a sequential two-step process of biomarker signature identification by supervised, multivariate, principal component analysis and verification by univariate ANOVA with Bonferroni correction. POTS patients were younger (26 vs. 31 years; p<0.001) and there was no significant difference in sex distribution (74% vs 67% females, p=0.24). PCA and Bonferroni-adjusted ANOVA identified proconvertase furin as the most robust biomarker signature for POTS. Plasma level of proconvertase furin was lower (6.38 vs. 6.58 of normalised protein expression units (NPX); p<0.001 in POTS, compared with the reference group. Proconvertase furin met Bonferroni-adjusted significance criteria in both uni- and multivariable regression analyses. Conclusion: Patients with Postural Orthostatic Tachycardia Syndrome have lower plasma level of proconvertase furin compared with individuals with normal postural hemodynamic response. This finding suggests the presence of a specific autoimmune trait with disruption of immune peripheral tolerance in this hitherto unexplained condition. Further studies are needed for external validation of our results.
No takes yet. Share an insight, caveat, or question.
Spahic et al. (2019) conducted a cross-sectional in Postural Orthostatic Tachycardia Syndrome (n=396). Postural Orthostatic Tachycardia Syndrome vs. Normal hemodynamic response was evaluated on Plasma level of proconvertase furin (NPX) (OR 0.86, 95% CI 0.77-0.96, p=0.009). Patients with Postural Orthostatic Tachycardia Syndrome had lower plasma levels of proconvertase furin compared to individuals with a normal hemodynamic response.
Synapse has enriched 10 related papers. Consider them for comparative context: